KINIKSA PHARMACEUTICALS LTD

NASDAQ: KNSA (Kiniksa Pharmaceuticals, Ltd.)

Last update: 13 Dec, 9:35PM

41.59

0.58 (1.41%)

  • 1D 1.41%
  • 5D 2.58%
  • 1M 0.02%
  • 6M 44.81%
  • YTD 108.58%
  • 1Y 105.38%
  • 5Y 112.09%
Previous Close 41.01
Open 41.06
Volume 298,908
Avg. Volume (3M) 426,584
Market Cap 3,152,345,600
Price / Earnings (TTM) 92.42
Price / Earnings (Forward) 30.67
Price / Sales 5.30
Price / Book 5.86
52 Weeks Range
17.82 (-57%) — 42.98 (3%)
Earnings Date 28 Oct 2025
Profit Margin -3.52%
Operating Margin (TTM) 9.63%
Diluted EPS (TTM) -0.240
Quarterly Revenue Growth (YOY) 72.50%
Total Debt/Equity (MRQ) 2.17%
Current Ratio (MRQ) 3.66
Operating Cash Flow (TTM) 44.03 M
Levered Free Cash Flow (TTM) 25.15 M
Return on Assets (TTM) -1.77%
Return on Equity (TTM) -3.81%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bullish Mixed
Stock Kiniksa Pharmaceuticals, Ltd. Bearish Bullish

AIStockmoo Score

0.4
Analyst Consensus 2.0
Insider Activity -4.0
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 0.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
KNSA 3 B - 92.42 5.86
LNTH 4 B - 27.07 3.95
ALVO 2 B - 23.96 -
PAHC 2 B 1.11% 36.50 5.24
BCRX 2 B - - 56.59
HROW 1 B - - 36.02

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Growth
% Held by Insiders 3.80%
% Held by Institutions 97.31%
52 Weeks Range
17.82 (-57%) — 42.98 (3%)
Price Target Range
44.00 (5%) — 60.00 (44%)
High 60.00 (TD Cowen, 44.27%) Buy
Median 50.00 (20.22%)
Low 44.00 (Wedbush, 5.80%) Buy
Average 50.80 (22.15%)
Total 5 Buy
Avg. Price @ Call 37.47
Firm Date Target Price Call Price @ Call
Goldman Sachs 29 Oct 2025 55.00 (32.24%) Buy 37.38
Citigroup 17 Oct 2025 50.00 (20.22%) Buy 38.64
Wedbush 13 Oct 2025 44.00 (5.79%) Buy 37.03
TD Cowen 29 Sep 2025 60.00 (44.27%) Buy 38.77
Wells Fargo 25 Sep 2025 45.00 (8.20%) Buy 35.51
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
QUART BARRY D - 41.55 -20,129 -836,360
RAGOSA MARK - 41.55 -42,841 -1,780,044
TESSARI EBEN - 41.55 -12,048 -500,594
Aggregate Net Quantity -75,018
Aggregate Net Value ($) -3,116,998
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 41.55
Name Holder Date Type Quantity Price Value ($)
TESSARI EBEN Officer 15 Dec 2025 Automatic sell (-) 12,048 41.55 500,594
TESSARI EBEN Officer 15 Dec 2025 Option execute 6,000 - -
QUART BARRY D Director 15 Dec 2025 Automatic sell (-) 20,129 41.55 836,360
QUART BARRY D Director 15 Dec 2025 Option execute 20,129 - -
RAGOSA MARK Officer 08 Dec 2025 Automatic sell (-) 42,841 41.55 1,780,044
RAGOSA MARK Officer 08 Dec 2025 Option execute 42,841 - -

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria